Publication | Closed Access

Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy

Heart FailureBone Marrow FailureCardiovascular DiseaseIschemic CardiomyopathyHematologyCell Replacement TherapyShort IschemiaIntracoronary AdministrationReperfusion InjuryMedicineCell TransplantationCardiologyIschemic SyndromeAnesthesiologyMyocardial Infarction